BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30700610)

  • 1. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.
    Christensen SR; Toulmin SA; Griesman T; Lamerato LE; Petrie JG; Martin ET; Monto AS; Hensley SE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
    Nachbagauer R; Shore D; Yang H; Johnson SK; Gabbard JD; Tompkins SM; Wrammert J; Wilson PC; Stevens J; Ahmed R; Krammer F; Ellebedy AH
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.
    Park JK; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
    mBio; 2018 Jan; 9(1):. PubMed ID: 29362240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.
    Kirchenbaum GA; Carter DM; Ross TM
    J Virol; 2016 Jan; 90(2):1116-28. PubMed ID: 26559834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.
    Sangster MY; Baer J; Santiago FW; Fitzgerald T; Ilyushina NA; Sundararajan A; Henn AD; Krammer F; Yang H; Luke CJ; Zand MS; Wright PF; Treanor JJ; Topham DJ; Subbarao K
    Clin Vaccine Immunol; 2013 Jun; 20(6):867-76. PubMed ID: 23576673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
    Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
    Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Park JK; Xiao Y; Ramuta MD; Rosas LA; Fong S; Matthews AM; Freeman AD; Gouzoulis MA; Batchenkova NA; Yang X; Scherler K; Qi L; Reed S; Athota R; Czajkowski L; Han A; Morens DM; Walters KA; Memoli MJ; Kash JC; Taubenberger JK
    Nat Med; 2020 Aug; 26(8):1240-1246. PubMed ID: 32601336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.
    Miller MS; Tsibane T; Krammer F; Hai R; Rahmat S; Basler CF; Palese P
    J Infect Dis; 2013 Jan; 207(1):98-105. PubMed ID: 23087428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
    Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
    mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.